Daiichi Sankyo Co Ltd

FDA approves Daiichi Sankyo’s Datroway as first‑line therapy for triple‑negative breast cancer, boosting the company’s oncology profile and investor confidence.

Discover how Daiichi Sankyo’s FDA‑approved ENHERTU® with pertuzumab and AI‑driven biomarker work reshape HER2‑positive breast cancer treatment, boosting clinical and market prospects.

Daiichi Sankyo Co Ltd is facing a significant legal challenge from IHH Healthcare’s subsidiary, while also launching a collaborative initiative to advance lung cancer treatment.